Transmucosal Drug Delivery Pipeline Research Report 2023: Formulate Effective R&D Strategies with Key Insights

DUBLIN, July 28, 2023 /PRNewswire/ — The “Transmucosal Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update” report has been added to ResearchAndMarkets.com’s offering.

The report provides comprehensive information about the Transmucosal Drug Delivery pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Transmucosal Drug Delivery device is intended for the localized delivery of medications through a mucous membrane.

Scope

Extensive coverage of the Transmucosal Drug Delivery under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Transmucosal Drug Delivery and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry

Reasons to Buy

Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Transmucosal Drug Delivery under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Transmucosal Drug Delivery Overview

3 Products under Development

3.1 Transmucosal Drug Delivery – Pipeline Products by Stage of Development

3.2 Transmucosal Drug Delivery – Pipeline Products by Segment

3.3 Transmucosal Drug Delivery – Pipeline Products by Territory

3.4 Transmucosal Drug Delivery – Pipeline Products by Regulatory Path

3.5 Transmucosal Drug Delivery – Pipeline Products by Estimated Approval Date

3.6 Transmucosal Drug Delivery – Ongoing Clinical Trials

4 Transmucosal Drug Delivery – Pipeline Products under Development by Companies

4.1 Transmucosal Drug Delivery Companies – Pipeline Products by Stage of Development

4.2 Transmucosal Drug Delivery – Pipeline Products by Stage of Development

5 Transmucosal Drug Delivery Companies and Product Overview

6 Transmucosal Drug Delivery – Recent Developments

7 Appendix

A selection of companies mentioned in this report includes

AcelRx Pharmaceuticals Inc
AFYX Therapeutics A/S
Albert Einstein College of Medicine
Allergan Ltd
Altamira Medica AG
Anelleo Inc
Aquestive Therapeutics Inc
Arovella Therapeutics Ltd
ARS Pharmaceuticals, Inc.
Atossa Therapeutics Inc
Auris Medical AG
Auritec Pharmaceuticals Inc
BeFree!
Bespak Europe Ltd
Biorings LLC
BioXcel Therapeutics Inc
Birmingham Biotech Ltd
Bryn Pharma LLC
Callitas Therapeutics Inc
Chulalongkorn University
Combinent BioMedical Systems Inc
Conrad
Covidrops LLP
Dare Bioscience Inc
Eledon Pharmaceuticals Inc
Emergent BioSolutions Inc
EmphyCorp Inc
Ena Respiratory Pty Ltd
Eureka Therapeutics Inc
Eveon SAS
Evestra Inc
Evofem Biosciences Inc
Ferring Pharmaceuticals AS
Firebrick Pharma Pty Ltd
GeneOne Life Science Inc
Ghent University
Glenmark Pharmaceuticals Ltd
Grasses of Eden Ltd
Grunenthal Ltd
Halberd Corp
Harm Reduction Therapeutics Inc
Hebrew University of Jerusalem
Hikma Pharmaceuticals Plc
Imbed Biosciences Inc
Institute for Research and Innovation in Health
Insys Therapeutics Inc (Inactive)
IntelGenx Corp
International Partnership For Microbicides
ITC Life Sciences and Technology Centre
ITF Pharma Inc
Janssen Sciences Ireland UC
Kane Biotech Inc
Karessa Pharma AB
Karp Lab
Kiora Pharmaceuticals Inc
Kytogenics Pharmaceuticals Inc
Laboratoire HRA Pharma SAS
Lachesis Biosciences Ltd
Leyden Laboratories BV
Lobe Sciences Ltd
Lyra Therapeutics Inc
Magee-Womens Research Institute
MassBiologics
McNeil AB
Medlab Clinical Ltd
Merck & Co Inc
Merck Serono SA
Mucommune LLC
Mycrodose Therapeutics Inc
Mystic Pharmaceuticals Inc
Nanosys Inc
Nasus Medical Inc
Nasus Pharma Ltd
Nemera La Verpilliere
NorInvent AB
Novlead Biotechnology Co Ltd
Olfax LLC
Opiant Pharmaceuticals Inc
OptiNose AS
OptiNose Inc
Organon Pharma (UK) Ltd
Orion Biotechnology Canada Ltd
Orphanse Healthcare SAS
Oyster Point Pharma Inc
P&B Group
Palette Life Sciences AB
Parnell Pharmaceuticals Inc
Phoenix Life Sciences International Ltd
pHOXBIO Ltd
Pocket Naloxone Corp
Polyrizon Ltd
RDD Pharma Ltd (Inactive)
Receptor Life Sciences Inc
Renown Pharmaceuticals Pvt Ltd
Rhinomed Ltd
Sanotize Research and Development Corp
Scientus Pharma Inc
Seelos Therapeutics, Inc.
Shin Nippon Biomedical Laboratories Ltd
SipNose Ltd
South Valley University
Starpharma Holdings Ltd
The Population Council Inc
Therakind Ltd
Union Therapeutics AS
University of California Davis
University of Erlangen-Nurnberg
University of Kentucky
University of Louisville
University of Melbourne
University of North Carolina at Chapel Hill
University of Pittsburgh
University of South Florida
University of Texas at Austin
University of the Witwatersrand
University of Waterloo
Virpax Pharmaceuticals Inc
VistaGen Therapeutics Inc
Washington University in St Louis
Wellfully Ltd
Xlear Inc
Zydus Healthcare Ltd

For more information about this report visit https://www.researchandmarkets.com/r/iqwt7j

Source: GlobalData

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[email protected]

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/transmucosal-drug-delivery-pipeline-research-report-2023-formulate-effective-rd-strategies-with-key-insights-301888239.html